News
12-13-2010, 05:31 AM
bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
More... (http://www.news-medical.net/news/20101213/bioTheranostics-reports-new-findings-from-study-evaluating-Breast-Cancer-Index-molecular-oncology-test.aspx)
More... (http://www.news-medical.net/news/20101213/bioTheranostics-reports-new-findings-from-study-evaluating-Breast-Cancer-Index-molecular-oncology-test.aspx)